10.07.25 -- Tyra Crystallizing The First Oral FGFR3 Therapy For Achondroplasia

Discover innovative strategies to boost CHO DG44 cell line productivity, as well as explore optimized expression systems that enhance yield, stability, and efficiency in protein development.

Consider using these three tools that facilitate a successful journey from candidate compound to clinical triumph: solid form screening, PBPK modeling, and AI-enabled route scouting.

Partnering with a CDMO that offers comprehensive and robust E&L studies can help facilitate a smooth product launch by ensuring minimal impact from impurities, all while mitigating risks.

Early-stage biopharma teams face tough choices in injectable development. A strategic middle ground may be the smartest path to avoid the risk of under- and overspending.

Watch how PBPK models combined with in vitro tools and solubility enhancement expertise can be used to identify and mitigate absorption risks in early drug development.

See how transposon technology is being reimagined as a genetic engineering tool to create high-performing CHO cell lines for biotherapeutic production with enhanced metabolic and glycan profiles.

Urine-derived cell-free DNA is revolutionizing liquid biopsy research to offer a non-invasive, accessible tool for early disease detection, monitoring, and comprehensive diagnostics across oncology.